SecSonar.com

Alkermes plc (ALKS)

Alkermes plc at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Alkermes plc (ALKS) is a Biotechnology company based in IE with a market capitalization of $7.1B. Revenue declined 5.3% year-over-year and the company generated $480.3M in free cash flow. This page tracks ALKS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

IE · 1.8K employees · IPO Jul 16, 1991

Valuation

Valuation & price

$36.95 · as of May 26, 2026 · -32.9% vs 52w high

25.8

P/E ratio

Latest-FY diluted EPS

3.91

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$55.08$40.60$26.13Jul 25Dec 25Jul 26Jul 7, 25$29.23Jul 9, 25$29.98Jul 11, 25$30.28Jul 15, 25$28.85Jul 17, 25$29.36Jul 21, 25$26.66Jul 23, 25$27.19Jul 25, 25$26.13Jul 29, 25$27.00Jul 31, 25$26.49Aug 4, 25$26.64Aug 6, 25$26.55Aug 11, 25$26.54Aug 13, 25$28.63Aug 15, 25$29.05Aug 19, 25$28.85Aug 21, 25$29.06Aug 25, 25$29.00Aug 27, 25$29.25Aug 29, 25$28.97Sep 3, 25$30.00Sep 5, 25$29.94Sep 9, 25$27.85Sep 11, 25$27.71Sep 16, 25$27.39Sep 18, 25$28.55Sep 22, 25$27.63Sep 24, 25$27.81Sep 26, 25$27.89Sep 30, 25$30.00Oct 2, 25$31.26Oct 6, 25$30.99Oct 8, 25$31.51Oct 10, 25$31.21Oct 14, 25$31.94Oct 16, 25$30.80Oct 21, 25$31.45Oct 23, 25$30.04Oct 27, 25$29.72Oct 29, 25$31.45Oct 31, 25$30.70Nov 4, 25$30.39Nov 6, 25$31.68Nov 10, 25$32.65Nov 12, 25$31.41Nov 14, 25$29.04Nov 18, 25$29.26Nov 20, 25$28.19Nov 25, 25$28.99Nov 28, 25$29.58Dec 2, 25$28.97Dec 4, 25$29.30Dec 8, 25$29.41Dec 10, 25$28.62Dec 12, 25$28.50Dec 16, 25$28.06Dec 18, 25$27.81Dec 22, 25$28.63Dec 24, 25$28.52Dec 29, 25$28.01Jan 2, 26$28.26Jan 6, 26$28.78Jan 8, 26$29.60Jan 12, 26$29.62Jan 14, 26$30.62Jan 16, 26$31.63Jan 21, 26$33.85Jan 23, 26$33.61Jan 27, 26$33.52Jan 29, 26$34.88Feb 2, 26$34.96Feb 4, 26$34.13Feb 9, 26$34.84Feb 11, 26$34.91Feb 13, 26$33.16Feb 18, 26$32.02Feb 20, 26$31.91Feb 24, 26$33.39Feb 26, 26$30.73Mar 2, 26$30.25Mar 4, 26$29.28Mar 6, 26$28.63Mar 10, 26$27.74Mar 12, 26$27.64Mar 17, 26$27.65Mar 19, 26$28.40Mar 23, 26$27.71Mar 25, 26$29.37Mar 27, 26$29.39Mar 31, 26$35.36Apr 2, 26$34.84Apr 7, 26$33.02Apr 9, 26$34.92Apr 13, 26$33.75Apr 15, 26$33.22Apr 17, 26$34.53Apr 22, 26$33.74Apr 24, 26$33.31Apr 28, 26$34.14Apr 30, 26$33.71May 4, 26$34.17May 6, 26$35.32May 8, 26$34.99May 12, 26$38.29May 14, 26$38.36May 18, 26$37.19May 20, 26$36.98May 22, 26$36.80May 28, 26$39.94Jun 1, 26$42.27Jun 3, 26$42.76Jun 5, 26$42.80Jun 9, 26$44.29Jun 11, 26$44.92Jun 15, 26$44.36Jun 17, 26$44.51Jun 22, 26$46.02Jun 24, 26$50.45Jun 26, 26$55.08Jul 2, 26$54.58
$26.1352-week range$55.08
Loading valuation history…

Fundamentals

Key fundamentals

$7.1B

Market cap

-5.3%

Revenue growth (YoY)

86.7%

Gross margin

$480.3M

Free cash flow (USD)

-$1.2B

Net debt

Net cash position

-0.4%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$745.7MFY 2017$903.4MFY 2018$1.1BFY 2019$1.2BFY 2020$1.0BFY 2021$1.2BFY 2022$1.1BFY 2023$1.7BFY 2024$1.6BFY 2025$1.5B
$745.7M$1.5B

Free cash flow by year

2016 → 2025

FY 2016$-107.5MFY 2017$-32.1MFY 2018$29.9MFY 2019$-18.9MFY 2020$40.6MFY 2021$72.7MFY 2022$-17.2MFY 2023$353.3MFY 2024$405.6MFY 2025$480.3M
-$107.5M$480.3M

Gross margin by year

2021 → 2025

FY 202183.2%FY 202280.4%FY 202384.8%FY 202484.3%FY 202586.7%
83.2%86.7%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

8

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 5, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $464K · 10b5-1 PlanHopkinson Craig C. · EVP R&D, Chief Medical Officer · $463.6KJul 1, 2026Filing
  • 8-K eventOrphan Drug DesignationJun 15, 2026Filing
  • Insider sellInsider Sell $90K · 10b5-1 PlanWright Christopher I · Director · $90.2KJun 12, 2026Filing
  • Insider sellInsider Sell $88K · 10b5-1 PlanGaffin David Joseph · EVP, CLO, Alkermes, Inc. · $87.6KJun 4, 2026Filing
  • Insider sellInsider Sell $375K · 10b5-1 PlanHopkinson Craig C. · EVP R&D, Chief Medical Officer · $375KJun 1, 2026Filing
  • Insider sellInsider Sell $687KParisi Samuel Joseph · VP, Finance (Interim PAO) · $687KMay 29, 2026Filing
  • 8-K eventStock Option Plan AmendmentMay 20, 2026Filing
  • 8-K eventPositive Study ResultsMay 12, 2026Filing
  • 8-K eventEarnings ReleaseMay 5, 2026Filing
  • Quarterly report10-Q FiledMay 5, 2026Filing

Questions

Frequently asked questions

What is Alkermes plc's market cap?

Alkermes plc (ALKS) has a market capitalization of $7.1B.

What is ALKS's P/E ratio?

ALKS trades at a price-to-earnings ratio of 25.8, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is ALKS's price-to-book (P/B) ratio?

ALKS trades at 3.91 times book value per share.

Are insiders buying ALKS stock?

SEC Form 4 filings show no open-market insider buys at Alkermes plc in the last 90 days (8 sells).

Same arena

Related companies in Biotechnology

PRAX

Praxis Precision Medicines, Inc.

$7.2B

CORT

Corcept Therapeutics Incorporated

$7.5B

KYMR

Kymera Therapeutics, Inc.

$6.7B

PTGX

Protagonist Therapeutics, Inc.

$6.4B

IBRX

ImmunityBio, Inc.

$7.9B

HALO

Halozyme Therapeutics, Inc.

$8B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.